Mrs Karina Benítez Lin
1Lunava, Mexico, Mexico
Biography:
Karina Elizabeth Benitez Lin is a Mexican psychologist with a bachelor’s degree in psychology (ITESO) and a Master of Science in Environmental Health from the University of Guadalajara (CUCBA). Her work integrates public health, environmental issues, and animal welfare, with a focus on social representations. She is trained in cognitive behavioural therapy (CBT) and third-wave therapies such as Acceptance and Commitment Therapy (ACT). She has collaborated with ITESO and CISAI in applied research and intervention projects. As of 2026, she is the co-founder of Lunava LAT.
Aims:
CBT adapted for menopause has demonstrated efficacy in reducing vasomotor, psychological, and sleep symptoms, yet evidence originates predominantly from high-income, English-speaking contexts. This study assessed feasibility and acceptability of a structured group CBT program for the menopause transition among women in Mexico, delivered in virtual and in-person formats.
Methods:
A feasibility study was conducted between December 2025 and February 2026. Nineteen women aged 40-60 in perimenopause or menopause participated: virtual (n=9) and in-person (n=10). Two sessions covering psychoeducation and cognitive restructuring were delivered. Feasibility indicators included early retention, emotional safety, and comprehension of the biopsychosocial model. A 60% retention benchmark was set as the minimum viability threshold.
Results:
Retention exceeded the benchmark in both formats: 77% virtual and 80% in-person. No critical safety events were recorded. Participants articulated mind-body connections and identified automatic thoughts. Neurochemical psychoeducation showed highest engagement. In-person sessions produced more intense emotional responses, requiring stronger facilitation for CBT fidelity.
Conclusions:
A group CBT program for menopause is feasible and acceptable among Latin American women, with retention rates comparable to Anglo-Saxon trials. Biopsychosocial framework adaptation appears a key engagement mechanism. A formal pilot incorporating MRS, PHQ-9, and GAD-7 is underway to generate clinical-grade outcome data.